Salubris(SZ:002294) Zheng Quan Zhi Xing·2025-08-19 17:47Core Insights - The company reported a main revenue of 2.131 billion yuan for the first half of 2025, representing a year-on-year increase of 4.32% [1] - The net profit attributable to shareholders reached 365 million yuan, up 6.1% year-on-year [1] - The second quarter of 2025 saw a single-quarter main revenue of 1.069 billion yuan, reflecting a 12.3% year-on-year growth [1] Financial Performance - The net profit for the second quarter was 165 million yuan, marking a 14.55% increase compared to the same quarter last year [1] - The non-recurring net profit for the first half of 2025 was 347 million yuan, which is a 3.93% increase year-on-year [1] - The second quarter's non-recurring net profit was 155 million yuan, showing a 16.98% year-on-year growth [1][5] Profitability Metrics - The company's debt ratio stands at 18.13% [1] - Investment income amounted to 19.61 million yuan, while financial expenses were -8.79 million yuan [1] - The gross profit margin is reported at 75.31%, which is an increase of 5.88% year-on-year [8] Earnings Per Share - Earnings per share (EPS) for the company is 0.33 yuan, reflecting a year-on-year increase of 6.45% [8] - The operating cash flow per share is reported at 0.38 yuan, which is a decrease of 20.19% year-on-year [8] Shareholder Information - The largest shareholder is Xintai Pharmaceutical Co., Ltd., holding 57% of shares [12] - Other significant shareholders include China Industrial Bank and Shenzhen Xintai Pharmaceutical Co., Ltd. [12][13]